An assessment of vancomycin use in 2 tertiary care hospitals

Canadian Journal of Hospital Pharmacy

Volumn 57, Issue 3, 2004, Pages 150-157

  Makowsky, Mark J ^a,b   Smith, Kelly K ^c   Ariano, Rob E ^d,e   Zhanel, George G ^f,g   Gin, Alfred S ^e  

^a WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d ST BONIFACE GENERAL HOSPITAL   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF MANITOBA   (Canada)

^g HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Drug use evaluation; Vancomycin; Vancomycin resistant enterococcus

Indexed keywords

BETA LACTAM ANTIBIOTIC; PENICILLIN G; VANCOMYCIN;

ADULT; ALERTNESS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG UTILIZATION; ENTEROCOCCUS; FEMALE; GASTROINTESTINAL SYMPTOM; GOVERNMENT REGULATION; GRAM POSITIVE BACTERIUM; HOSPITAL CARE; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFORMATION SYSTEM; LARYNX SPASM; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; NAUSEA; PATIENT SELECTION; PRACTICE GUIDELINE; PRESCRIPTION; RISK FACTOR; URTICARIA;

EID: 3242689860     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520-32.
2. Gin AS, Zhanel GG. Vancomycin-resistant enterococci. Ann Pharmacother 1996;30:615-24.
3. Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;1:57-8.
4. Martone WJ. Spread of vancomycin-resistant enterococci: Why did it happen in the United States? Infect Control Hosp Epidemiol 1998;19:539-45.
5. Iwen PC, Kelly DM, Lander J, Hinrichs SH, Dominguez EA, Rupp ME, et al. Change in prevalence and antibiotic resistance of Enterococcus species isolated from blood cultures over an 8-year period. Antimicrob Agents Chemother 1997;41:494-5.
6. Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC. Characterization of glyocpeptide-resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother 1993;37:2311-7.
7. Murray B. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342(10):710-21.
8. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23(6):1234-9.
9. Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR Morb Mortal Wkly Rep 1997;46:624-4.
10. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:765-6. Erratum in: MMWR Morb Mortal Wkly Rep 1997;46:851.
11. Sanyal D, Johnson AP, George RC, Cookson BD, Williams AJ. Peritonitis due to vancomycin resistant Staphylococcus epidermidis. Lancet 1991;337:54.
12. Krcmery V Jr, Trupl J, Drogona L, Lacka J, Krukuckova E, Oravocova E. Nosocomial bacteremia due to vancomycin-resistant Staphylococcus epidermidis in four patients with cancer, neutropenia, and previous treatment with vancomycin. Eur J Clin Microbiol Infect Dis 1996;15:259-61.
13. Shay DK, Goldmann DA, Jarvis WR. Reducing the spread of antimicrobial resistant microorganisms: control of vancomycin resistant enterococci. Pediatr Clin North Am 1995;42:703-16.
14. Moreno F, Grota P, Crisp C, Magnon K, Melcher GP, Jorgensen JH, et al. Clinical and molecular epidemiology of vancomycin resistant Enterococcus faecium during its emergence in a city in southern Texas. Clin Infect Dis 1995;21:1234-7.
15. Morris JG Jr, Shay DK, Hebden JN, McCarter RJ Jr, Perdue BE, Jarvis W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250-9.
16. Karanfil LV, Murphy M, Josephson A, Gaynes R, Mandel L, Hill BC, et al. A cluster of vancomycin resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992;13:195-200.
17. Boyle JF, Soumakis SA, Rendo A, Herrington JA, Gianarkis DG, Thurburg BE, et al. Epidermologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993;31:1280-5.
18. Livornese LL Jr, Dias S, Sarnel C, Romanowski B, Taylor S, May P, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992;117:112-6.
19. Weinstein JW, Roe M, Towns M, Sanders L, Thorpe JJ, Corey GR, et al. Resistant enterococci: a prospective study of prevalence, incidence, and factors associated with colonization in a university hospital. Infect Control Hosp Epidemiol 1996;17:36-41.
20. Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995;20:1126-33.
21. Health Canada, Laboratory Centre for Disease Control, Bureau of Infectious Diseases, Division of Nosocomial and Occupational Infectious Diseases, VRE Working Group, Canadian Hospital Epidemiology Committee. Preventing the spread of vancomycin resistant enterococci (VRE) in Canada. Can Commun Dis Rep 1997;23 Suppl 8:i-iv, 1-19.
22. Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother 2003;51 Suppl 3:iii13-21.
23. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1995;44(RR-12):1-13.
24. Johnson SV, Hoey LL, Vance-Bryan K. Inappropriate vancomycin prescribing based on criteria from the Centers for Disease Control and Prevention. Pharmacotherapy 1995;15:579-85.
25. Wright SW, Wrenn KD. Appropriateness of vancomycin use in the emergency department. Ann Emerg Med 1998;32:531-6.
26. Anglim AM, Klym B, Byers KE, Scheld WM, Farr BM. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium. Arch Intern Med 1997;157:1132-6.
27. Misan GM, Martin ED, Smith ER, Somogyi AA, Bartholomeusz RC, Bochner F. Drug utilization review in a teaching hospital: experience with vancomycin. Eur J Clin Pharmacol 1990;39:457-61.
28. Morgan AS, Brennan PJ, Fishman NO. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant enterococcus. Ann Pharmacother 1997;31:970-3.
29. Phillips E, Louie M, Knowles SR, Simor AE, Oh PI. Cost-effectiveness analysis of six strategies for cardiovascular surgery prophylaxis in patients labeled penicillin allergic. Am J Health Syst Pharm 2000;57:339-45.